Paradigm Biopharmaceuticals Limited
Research Paradigm Biopharmaceuticals Limited (P86) on Bullrun: market cap EUR 63.51M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerP86
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 63.51M
- Financial periodFY2024
- RevenueAUD 65.80K
- Revenue growth40.7%
- Net income-AUD 58.65M
- Free cash flow-AUD 65.94M
- Gross margin86.3%
Valuation Snapshot
latest market cap is EUR 63.51M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2024 | AUD 65.80K | -AUD 58.65M | -AUD 65.94M | 86.3% | -0.2 | AUD 17.82M | AUD 239.33K | AUD 23.81M |
| FY2023 | AUD 46.76K | -AUD 51.91M | -AUD 45.19M | 59.7% | -0.18 | AUD 56.33M | AUD 341.67K | AUD 53.68M |
| FY2022 | AUD 79.22K | -AUD 39.25M | -AUD 32.21M | -81.4% | -0.16 | AUD 39.67M | AUD 616.67K | AUD 42.31M |
| FY2021 | AUD 20.55K | -AUD 34.30M | -AUD 34.96M | -382.4% | -0.16 | AUD 71.03M | AUD 751.84K | AUD 78.27M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 63.51M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Paradigm Biopharmaceuticals Limited
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Paradigm Biopharmaceuticals Limited's market cap?
Paradigm Biopharmaceuticals Limited's market capitalization is EUR 63.51M.
What does Paradigm Biopharmaceuticals Limited do?
Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. Its lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.